Systemic Exposure of Rituximab Increased by Ibrutinib: Pharmacokinetic Results and Modeling Based on the HELIOS Trial

Lavezzi, Silvia; de Jong, Jan; Neyens, Martine; Cramer, Paula; DEMİRKAN, FATİH; Fraser, Graeme; Bartlett, Nancy; Dilhuydy, Marie-Sarah; Loscertales, Javier; Avigdor, Abraham; Rule, Simon; Samoilova, Olga; Goy, Andre; Ganguly, Siddhartha; Salman, Mariya; Howes, Angela; Mahler, Michelle; De Nicolao, Giuseppe; Poggesi, Italo

doi:10.1007/s11095-019-2605-8

Systemic Exposure of Rituximab Increased by Ibrutinib: Pharmacokinetic Results and Modeling Based on the HELIOS Trial

Atıf İçin Kopyala

Lavezzi S. M., de Jong J., Neyens M., Cramer P., DEMİRKAN F., Fraser G., ...Daha Fazla

PHARMACEUTICAL RESEARCH, cilt.36, sa.7, 2019 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 36 Sayı: 7
Basım Tarihi: 2019
Doi Numarası: 10.1007/s11095-019-2605-8
Dergi Adı: PHARMACEUTICAL RESEARCH
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Anahtar Kelimeler: bendamustine, ibrutinib, modeling, pharmacokinetics, rituximab, CHRONIC LYMPHOCYTIC-LEUKEMIA, MULTICENTER PHASE-II, TARGET, BENDAMUSTINE, ASSOCIATION, ELIMINATION, CLEARANCE, BTK
Dokuz Eylül Üniversitesi Adresli: Evet

Özet

Introduction In the HELIOS trial, bendamustine/rituximab (BR) plus ibrutinib (BR-I) improved disease outcomes versus BR plus placebo in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma. Here, we describe the pharmacokinetic (PK) observations, along with modeling to further explore the interaction between ibrutinib and rituximab.